Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SSGJ-626 in Active Cutaneous Lupus Erythematosus
NCT07900867Phase 2Not yet recruiting
- Sponsor
- 3S Guojian Pharmaceutical
- Start
- Nov 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
A Phase 2 trial of 626 in cutaneous lupus erythematosus (CLE), sponsored by 3S Guojian Pharmaceutical. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
626
03
Conditions
cutaneous lupus erythematosus (CLE)
Beyond the preview
Go deeper on NCT07900867.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07900867.